» Articles » PMID: 35536538

Improving the Prediction of Potential Kinase Inhibitors with Feature Learning on Multisource Knowledge

Overview
Journal Interdiscip Sci
Specialty Biology
Date 2022 May 10
PMID 35536538
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The identification of potential kinase inhibitors plays a key role in drug discovery for treating human diseases. Currently, most existing computational methods only extract limited features such as sequence information from kinases and inhibitors. To further enhance the identification of kinase inhibitors, more features need to be leveraged. Hence, it is appealing to develop effective methods to aggregate feature information from multisource knowledge for predicting potential kinase inhibitors. In this paper, we propose a novel computational framework called FLMTS to improve the performance of kinase inhibitor prediction by aggregating multisource knowledge.

Method: FLMTS uses a random walk with restart (RWR) to combine multiscale information in a heterogeneous network. We used the combined information as features of compounds and kinases and input them into random forest (RF) to predict unknown compound-kinase interactions.

Results: Experimental results reveal that FLMTS obtains significant improvement over existing state-of-the-art methods. Case studies demonstrated the reliability of FLMTS, and pathway enrichment analysis demonstrated that FLMTS could also accurately predict signaling pathways in disease treatment.

Conclusion: In conclusion, our computational framework of FLMTS for improving the prediction of potential kinase inhibitors successfully aggregates feature information from multisource knowledge, yielding better prediction performance than existing state-of-the-art methods.

Citing Articles

Speos: an ensemble graph representation learning framework to predict core gene candidates for complex diseases.

Ratajczak F, Joblin M, Hildebrandt M, Ringsquandl M, Falter-Braun P, Heinig M Nat Commun. 2023; 14(1):7206.

PMID: 37938585 PMC: 10632370. DOI: 10.1038/s41467-023-42975-z.

References
1.
Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

2.
Levitzki A . Protein kinase inhibitors as a therapeutic modality. Acc Chem Res. 2003; 36(6):462-9. DOI: 10.1021/ar0201207. View

3.
Muller S, Chaikuad A, Gray N, Knapp S . The ins and outs of selective kinase inhibitor development. Nat Chem Biol. 2015; 11(11):818-21. DOI: 10.1038/nchembio.1938. View

4.
Bhullar K, Lagaron N, McGowan E, Parmar I, Jha A, Hubbard B . Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018; 17(1):48. PMC: 5817855. DOI: 10.1186/s12943-018-0804-2. View

5.
Fedorov O, Muller S, Knapp S . The (un)targeted cancer kinome. Nat Chem Biol. 2010; 6(3):166-169. DOI: 10.1038/nchembio.297. View